Member
-
PET/MRI Machine Learning Model Can Eliminate Sentinel Lymph Node Biopsy in Majority of Breast Cancer Patients
Nov 10, 2022
—
Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy, according to new research published in JNM.
-
CTN: Enabling Accurate Quantitative PET/CT and SPECT/CT Imaging
Oct 25, 2022
—
Quantitative measurements have long been a strength of nuclear medicine. There is renewed urgency for accurate, reproducible, and standardized measurements in routine clinical practice as the role of diagnostic and therapeutic radiopharmaceuticals in clinical trials and routine clinical care grows. The CTN continues to be involved in this space, with several active projects to address this need.
-
Novel PET Imaging Agent Detects Earliest Signs of Alzheimer’s Disease
Oct 19, 2022
—
A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B (MAO-B) in cognitively unimpaired individuals with high beta amyloid, according to research published in the October issue of JNM.
-
Ultra-Low Dose Total Body PET/CT Effective for Evaluating Arthritis
Oct 12, 2022
—
Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of JNM.
-
SNMMI and the Lobular Breast Cancer Alliance Announce $100,000 Research Grant
Oct 3, 2022
—
SNMMI announces a new $100,000 grant to fund research on nuclear medicine imaging and treatments for lobular beast cancer. The grant is sponsored by the SNMMI Mars Shot Fund and the Lobular Breast Cancer Alliance.
-
New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms
Sep 28, 2022
—
A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms, according to research published in September JNM, and may also serve as a potential target for peptide radionuclide therapy (PRRT) for NEN patients.
-
TerraPower Announces Funding Raised for Nuclear Technologies
Sep 20, 2022
—
TerraPower, a nuclear innovation company founded by Bill Gates, announced a $750 million funding raise co-led by Gates and SK, a large South Korean conglomerate that is one of South Korea’s largest energy providers. According to a press release from TerraPower, this effort will enhance the company’s “groundbreaking work in advanced nuclear energy technologies and nuclear medicine.”
-
SNMMI PR Campaign Lands Stories in Major Media Markets
Sep 12, 2022
—
SNMMI’s consumer-focused public relations initiative to raise awareness about what nuclear medicine is and what it can accomplish has seen continued success in the summer months.
-
A Special Issue of the Journal of Nuclear Medicine Technology Highlights the New Frontier of Theranostics
Sep 12, 2022
—
A special issue of the Journal of Nuclear Medicine Technology focuses on theranostics as it relates to technologists and includes articles on quality and practice management, imaging, and radiation safety, as well as continuing education articles.
-
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50 Percent of Prostate Cancer Patients
Sep 7, 2022
—
In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as compared to imaging with CT alone.
-
Francoeur to Lead Patient Advocacy Advisory Board for Society of Nuclear Medicine and Molecular Imaging
Aug 11, 2022
—
Jeri Francoeur of Ormond Beach, Florida, has been elected to a two-year term as chair of SNMMI's Patient Advocacy Advisory Board.
-
Crosby Elected Vice Chair of Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging
Aug 11, 2022
—
Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of SNMMI's Patient Advocacy Advisory Board.